Low Incidence Medical Conditions With High Potential

Ipsos-Insight Health Research Identifies Niche Market Opportunities

New York, NY -- Low incidence conditions are often overlooked in the current pharmaceutical market; a climate characterized by fierce competition and head-to-head rivalry for the most profitable therapeutic areas. But Ipsos-Insight Health, a member of the Ipsos Group, a leading global survey-based market research company, has identified 33 low-incidence conditions that could be cost-effective and lucrative niche market opportunities. Using the Ipsos-Insight Sufferer Panel, researchers identified gastric ulcers, heart attacks, shingles and kidney disease as conditions with an incidence rate of less than 1% that merit further consideration. These four conditions are more prevalent than other low incidence medical conditions (those below 1% incidence) and represent a larger number of untreated individuals. Gastric ulcer and shingles also have a smaller proportion of sufferers using prescription drug therapy. Using the Ipsos-Insight Sufferer Panel of over 200,000 individuals, researchers analyzed the extent of treatment for the condition, the extent of treatment with prescription drugs, the size of the patient population, and the size of the untreated group, to determine which low-incidence conditions might represent opportunities. Researchers also identified motion sickness, anemia, osteoporosis, and attention deficit hyperactive disorder (ADHD) as medical conditions with an incidence rate of 2-3% that warrant further assessment. The proportion of individuals that are not currently treating with a prescription drug, particularly among sufferers of motion sickness and anemia. offer a real opportunity for further development. These low incidence conditions translate into patient populations ranging between 2 and 9 million individuals, and the size of the untreated populations can be as large as 3.5 million. "The more than 30 medical conditions with small patient groups present attractive marketing opportunities because new emerging channels of communication mean they can be targeted cost-efficiently," said Nancy Forni, Director of Ipsos-Insight. "Organizations that are willing to think and act creatively can reach these groups effectively by direct mail, print, orthe Internet." Methodology The Ipsos-Insight Sufferer Panel consists of over 200,000 individuals who have been screened for 70+ medical conditions, at least 30 of which are low incidence conditions. This panel is an ideal sampling source for healthcare marketing research. It is also a valuable source for understanding key sufferer groups in greater detail. For more information, please contact: Nancy Forni Director Ipsos PharmTrends 516.507.3256 View previous research highlights publicly released by Ipsos-Insight Health. About Ipsos-Insight Ipsos-Insight is a member of the Ipsos Group, a leading global survey-based market research company. As the company's flagship marketing research division in the U.S., Ipsos-Insight provides custom and tracking research to domestic clients as well as U.S.-based multinationals. Ipsos-Insight specializes in research for the Consumer Products, Technology & Communications, Financial Services, and Health industries, to name a few. It also acts as the portal to other Ipsos specializations including advertising research, forecasting, modeling, global research, public opinion research, and customer loyalty research. Let Ipsos-Insight client service representatives help you access more than 4,000 Ipsos research professionals and field staff located coast-to-coast, and around the world. To learn more, visit: www.ipsos-insight.com. About Ipsos Ipsos is a leading global survey-based market research group, with revenues of 538.5 million euros in 2002. It offers a full suite of research services, guided by industry experts and bolstered by advanced analytics and methodologies in advertising, marketing, public opinion and customer loyalty research, as well as forecasting and modeling. Member companies also offer a full line of custom, syndicated, omnibus, panel, and online research products and services. To learn more, visit: www.ipsos.com. Ipsos is listed on the Euronext Paris Premier Marchй, and is part of the SBF 120 and Next Prime Indices as well as eligible to the Deferred Settlement System (SRD). Euroclear code 7329, Reuters ISOS.LN, Bloomberg IPS FP

More insights about Health